Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
J. D. Lundgren et al.
Summary: The study aimed to evaluate the efficacy and safety of bamlanivimab in COVID-19 patients, with results indicating potential benefits in patients without neutralizing antibodies at baseline. However, due to the limited sample size, further research is needed to assess the effects of other types of passive immune therapies in the same patient setting.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Biophysics
Chikara Ogimi et al.
Summary: In this study, we assessed novel factors and the immunodeficiency scoring index (ISI) to predict progression to lower respiratory tract infection (LRTI) among hematopoietic cell transplant (HCT) recipients with upper respiratory tract infection (URTI) in the PCR era. We found that a history of multiple transplants, age ≥ 40 years, time post-HCT ≤ 30 days, systemic steroids, hypoalbuminemia, hyperglycemia, cytopenia, and high ISI scores were associated with an increased risk of progression to LRTI.
BONE MARROW TRANSPLANTATION
(2022)
Article
Microbiology
Tomer Zohar et al.
Summary: Through studying a nonhuman primate-challenge model, we found that immune protection against RSV infection is associated with antibody levels, neutralization, complement activity, and Fc-mediated effector mechanisms. These findings provide important insights for the development of future vaccines.
CELL HOST & MICROBE
(2022)
News Item
Medicine, General & Internal
[Anonymous]
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE
(2022)
Article
Multidisciplinary Sciences
Lihong Liu et al.
Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.
Article
Multidisciplinary Sciences
Peter B. Gilbert et al.
Summary: In the COVE phase 3 clinical trial, neutralizing and binding antibodies were measured in vaccine recipients to determine their correlation with COVID-19 risk and vaccine efficacy. The results showed that these immune markers were inversely associated with COVID-19 risk and directly associated with vaccine efficacy. Postvaccination neutralization titers of 10, 100, and 1000 correlated with estimated vaccine efficacies of 78%, 91%, and 96% respectively.
Review
Immunology
Moazzam Shahzad et al.
Summary: This study analyzed data from 19 original studies and found that HSCT recipients have a high risk of mortality and clinical complications due to COVID-19, emphasizing the need for ongoing vigilance and aggressive management.
TRANSPLANT INFECTIOUS DISEASE
(2022)
Article
Respiratory System
Ricardo J. Jose et al.
Summary: Respiratory diseases, including viral bronchitis, bronchiolitis obliterans syndrome (BOS) and bronchiectasis, are common in patients with hematologic malignancies. Early identification of patients and appropriate treatment strategies can improve treatment efficacy, halt lung function decline, and enhance quality of life.
EXPERT REVIEW OF RESPIRATORY MEDICINE
(2022)
Review
Pediatrics
Asaf Yanir et al.
Summary: Immune reconstitution after allogeneic hematopoietic cell transplantation is crucial for transplant outcomes. Younger children experience faster immune cell recovery, leading to lower rates of graft vs. host disease and complications. Strategies to influence immune reconstitution are still evolving. Recovery of antigen-specific immune cells plays a significant role in protecting against viral diseases, while the association between immune reconstitution and graft vs. leukemia effect is less understood. Future improvements in immune reconstitution may impact transplant procedures.
FRONTIERS IN PEDIATRICS
(2022)
Article
Immunology
Paul S. Kim et al.
Summary: This retrospective cohort study compared the serologic responses of COVID-19 patients who received monoclonal antibody treatment with those who did not. The findings showed that all monoclonal antibody treatments greatly suppressed the anti-spike IgM response, but had minor effect on the anti-nucleocapsid response.
CLINICAL IMMUNOLOGY
(2022)
News Item
Infectious Diseases
Sharmila Devi
LANCET INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Myron J. Levin et al.
Summary: A single dose of AZD7442 showed efficacy in preventing Covid-19 without evident safety concerns. The study suggests that AZD7442 may provide potential protection for individuals who have an inadequate response to vaccination or an increased risk of exposure.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Laura L. Hammitt et al.
Summary: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Multidisciplinary Sciences
Sho Iketani et al.
Summary: The identification of the Omicron variant of SARS-CoV-2 in Botswana in November 2021 sparked concern due to the spike protein alterations that could potentially evade antibodies. Further studies showed that the Omicron sublineages, BA.1+R346K and BA.2, are antigenically similar to the wild-type virus and pose similar risks to the effectiveness of current vaccines. BA.2 also demonstrated resistance to many neutralizing monoclonal antibodies, highlighting the challenges in developing effective therapeutic options.
Review
Cell Biology
Yu-Chyi Hwang et al.
Summary: The COVID-19 pandemic has created a public health crisis, leading to the urgent development of therapeutic treatments and virus detection methods. Monoclonal antibodies (mAbs) have emerged as powerful tools for treating and detecting diseases due to their high specificity and reliability. Researchers are urgently developing antibody-based kits for SARS-CoV-2 detection and antibody drugs for COVID-19 treatment. The spike protein of SARS-CoV-2, which is crucial for viral infection, has been extensively studied and its receptor-binding domain (RBD) has become a major target for therapeutic antibody development. Given the high mutation rate of SARS-CoV-2, especially under the pressure of prophylactic vaccines and neutralizing antibodies, the use of antibody cocktails is expected to be an important strategy for effective COVID-19 treatment. Additionally, antibodies against cytokine storms, which can be triggered by SARS-CoV-2 infection and drive severe disease progression, are also being developed as treatments for COVID-19. In addition to their use as drugs, antibodies are currently being used in SARS-CoV-2 detection tests, including antigen and immunoglobulin tests, which are crucial surveillance tools for preventing the spread of COVID-19.
JOURNAL OF BIOMEDICAL SCIENCE
(2022)
Article
Immunology
Eric A. F. Simoes et al.
Summary: The study indicates that suptavumab did not reduce the overall rate of childhood RSV respiratory infections due to a newly circulating mutant strain of RSV B. Genetic variation in circulating RSV strains will continue to pose challenges to prevention efforts.
CLINICAL INFECTIOUS DISEASES
(2021)
Article
Microbiology
Allison J. Greaney et al.
Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.
CELL HOST & MICROBE
(2021)
Article
Multidisciplinary Sciences
Steven A. Kemp et al.
Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.
Article
Medicine, General & Internal
Brian M. Maas et al.
Summary: A model-based meta-analysis was conducted to establish the relationship between RSV serum neutralizing activity and clinical outcomes, enabling the prediction of the prophylactic efficacy of MK-1654 in infants. The results were consistent with animal challenge experiments and clinical trial data, indicating the potential for the MBMA approach to predict efficacy of neutralizing antibodies against RSV and other respiratory pathogens.
Article
Medicine, General & Internal
Francesco Menichetti et al.
Summary: The clinical trial comparing convalescent plasma (CP) plus standard therapy (ST) with ST alone in hospitalized patients with COVID-19 pneumonia showed that high-titer anti-SARS-CoV-2 CP did not reduce the progression to severe respiratory failure or death within 30 days.
Article
Biochemistry & Molecular Biology
David S. Khoury et al.
Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.
Review
Infectious Diseases
Christiane S. Eberhardt et al.
Summary: COVID-19 vaccination is considered a promising strategy to control the pandemic, but data on benefits and risks in immunocompromised individuals, such as transplant recipients, are limited. It is strongly recommended to prioritize vaccination for these vulnerable populations to decrease morbidity and mortality.
CURRENT OPINION IN INFECTIOUS DISEASES
(2021)
Article
Oncology
Per Ljungman et al.
Summary: The study reveals that COVID-19 patients who have undergone allogeneic or autologous hematopoietic cell transplantation are at high risk of developing lower respiratory tract disease, requiring ICU admission, and have increased mortality rates.
Article
Multidisciplinary Sciences
Rachel Yamin et al.
Summary: Monoclonal antibodies with optimized Fc domains show superior potency in preventing and treating COVID-19 in animal disease models, reducing the dose required for protection against SARS-CoV-2 challenge and for treating pre-infected animals. Selective engagement of activating Fc receptors results in improved efficacy, highlighting the importance of Fc receptor pathways in driving antibody-mediated antiviral immunity. These findings have implications for the development of Fc-engineered monoclonal antibodies with optimal Fc-effector function against COVID-19.
Article
Multidisciplinary Sciences
Zhiqiang Ku et al.
Summary: A newly engineered IgM neutralizing antibody, IgM-14, demonstrates over 230-fold higher potency in neutralizing SARS-CoV-2 compared to the parental IgG-14. IgM-14 also displays strong neutralizing activity against resistant virus variants and receptor-binding domain mutants, indicating its potential as an effective therapy for COVID-19.
Article
Multidisciplinary Sciences
Jianliang Xu et al.
Summary: The study found that camelid nanobodies can effectively circumvent vaccine escape caused by mutations in the novel coronavirus. These nanobodies are able to neutralize SARS-CoV-2 variants through two mechanisms, demonstrating promising potential in preventing COVID-19 mortality when vaccines are compromised.
Article
Medicine, General & Internal
Frederick K. Korley et al.
Summary: This study showed that administering Covid-19 convalescent plasma to high-risk outpatients within 1 week after symptom onset did not prevent disease progression.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Editorial Material
Medicine, General & Internal
Lawrence Corey et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, Research & Experimental
Jim Boonyaratanakornkit et al.
Summary: HPIV3 is a common respiratory pathogen that can be fatal in vulnerable populations. A study identified an antibody, PI3-E12, that effectively neutralizes HPIV3 and can be used prophylactically and therapeutically, demonstrating potential clinical utility for the prevention and treatment of HPIV3 in both immunocompetent and immunocompromised individuals.
Article
Cell Biology
Michael S. Piepenbrink et al.
Summary: The fully human monoclonal antibody 1212C2, derived from an IgM memory B cell of a COVID-19 patient, shows high affinity for the Spike protein receptor binding domain and effectively neutralizes SARS-CoV-2. When delivered intraperitoneally in hamsters, it demonstrates in vivo prophylactic and therapeutic activity in reducing viral burden and lung pathology in the respiratory tract.
CELL REPORTS MEDICINE
(2021)
Article
Multidisciplinary Sciences
Alina Baum et al.
Review
Immunology
Kevin O. Saunders
FRONTIERS IN IMMUNOLOGY
(2019)
Review
Immunology
Elisabeth A. van Erp et al.
FRONTIERS IN IMMUNOLOGY
(2019)
Article
Pharmacology & Pharmacy
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
(2017)
Article
Pharmacology & Pharmacy
Liang Zhao et al.
JOURNAL OF CLINICAL PHARMACOLOGY
(2013)
Article
Biochemistry & Molecular Biology
William F. Dall'Acqua et al.
JOURNAL OF BIOLOGICAL CHEMISTRY
(2006)
Article
Immunology
M Boeckh et al.
JOURNAL OF INFECTIOUS DISEASES
(2001)
